The ascent of the blessed: regulatory issues on health effects and health claims for probiotics in Europe and the rest of the world

The outcome of the first series of health claim applications for probiotics in Europe as evaluated by the European Food Safety Authority (EFSA) has, up to 2013 almost completely yielded negative results. All recent applications also have been rejected, including the latest on prevention of mastitis...

Full description

Saved in:
Bibliographic Details
Published inBeneficial microbes Vol. 9; no. 5; p. 717
Main Authors Dronkers, T M G, Krist, L, Van Overveld, F J, Rijkers, G T
Format Journal Article
LanguageEnglish
Published Netherlands 18.09.2018
Subjects
clinical trials
Bifidobacterium
EFSA
Lactobacillus
Online AccessGet more information

Cover

More Information
Summary:The outcome of the first series of health claim applications for probiotics in Europe as evaluated by the European Food Safety Authority (EFSA) has, up to 2013 almost completely yielded negative results. All recent applications also have been rejected, including the latest on prevention of mastitis in breastfeeding mothers. In other developed countries, such as Switzerland, Japan and Canada, the health effects of probiotics, for which scientific evidence has been provided, can be communicated to potential consumers. The number of clinical trials with probiotics over recent years shows a trend to level off or even decline. At the same time, clinical research into the role of (gut) microbiota in a wide variety of diseases and conditions is booming. Ultimately, this may offer new indications for gut microbiota management by probiotics, prebiotics or other food supplements.
ISSN:1876-2891
DOI:10.3920/BM2017.0196